BioSpace News Archive

Stanford Medicine announced today that it will be participating in the ongoing Phase 3 clinical trial of NOVOCART® 3D, an investigational autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee

LabVoice, which provides a workflow engine for scientific voice assistants, and IDBS, a leading R&D technology and solutions provider, are excited to announce an integration to accelerate research, innovation, and design

FDA Fast Track Designation has been granted to DAV132 for the prevention of Clostridioides difficile infection, a life-threatening condition with persistent unmet medical need, especially in cancer patients

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 1,400,000 depositary shares at an initial public offering price of $25.00 per depositary share, raising gross proceeds of $35.0 million before deducting underwriting discounts and other estimated offering expenses.

FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.

CM Life Sciences III Inc. announced that it priced its initial public offering of 48,000,000 units at $10.00 per unit.

TransMedics Group, Inc. announced that after the review of TransMedics’ clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration has issued a favorable vote in support of approval of the OCS Heart System to the FDA’s Office of Health Technology 2.